Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Four Concentrations of Intraperitoneal NanoPac Plus Six Cycles of IV Carboplatin and Paclitaxel in Patients With Platinum-Sensitive Recurrent Stage III Epithelial Ovarian Cancer Undergoing Second Cytoreductive Surgery

Trial Profile

Phase II Study of Four Concentrations of Intraperitoneal NanoPac Plus Six Cycles of IV Carboplatin and Paclitaxel in Patients With Platinum-Sensitive Recurrent Stage III Epithelial Ovarian Cancer Undergoing Second Cytoreductive Surgery

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2019

At a glance

  • Drugs Paclitaxel (Primary) ; Carboplatin; Paclitaxel
  • Indications Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Nanology
  • Most Recent Events

    • 10 Jan 2019 Status changed from recruiting to active, no longer recruiting.
    • 31 Aug 2018 Biomarkers information updated
    • 09 Oct 2017 According to a Nanology media release, the first patient has been enrolled in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top